Global investment firm TPG has signed a legally binding agreement to purchase a 35% ownership in SCHOTT Poonawalla, the joint venture between Serum Institute of India (SII) and Germany-based SCHOTT ...

Global investment firm TPG has entered into a binding agreement to acquire a 35% stake in SCHOTT Poonawalla Pvt Ltd, a ...

TPG, a global alternative asset management firm, has entered into a binding agreement to acquire a 35% stake in SCHOTT ...

TPG acquires 35% stake in SCHOTT Poonawalla from Serum Institute of India; SCHOTT Pharma retains 50% while SII continues as ...

TPG will acquire a 35% stake in SCHOTT Poonawalla from the Serum Institute of India. This joint venture with SCHOTT Pharma is ...

Global alternative asset firm TPG has acquired a 35% stake in SCHOTT Poonawalla, a joint venture between SCHOTT Pharma and ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

SCHOTT Poonawalla is a joint venture of SCHOTT Pharma and SII, part of the Cyrus Poonawalla Group and a global leader in vaccine manufacturing, dedicated to providing affordable vaccines worldwide.

TPG Growth, TPG’s middle market and growth equity platform, is funding the investment, along with Novo Holdings as a ...

SCHOTT Pharma, a provider of drug containment solutions and delivery systems for injectable drugs, announced that TPG — a ...

TPG is acquiring a 35% stake in SCHOTT Poonawalla, a joint venture of SCHOTT Pharma and Serum Institute of India. The deal is ...